Another study revealed that through selective suppression of Akt and MAPK signaling, the interaction of SLAMF1 and CD180 receptor pathways contributes to the pathobiology of B cell CLL (87). This evidence concerns the gene SLAMF1 and B-cell chronic lymphocytic leukemia.